#RNL2023 Year in Review Male response better than female response in patients with PsA in SELECT-PsA evaluating UPA/ADA. More targeted studies needed @RheumNow https://t.co/Z3kbM0e9A0

Should we be measuring HCQ levels? - note HCQ doses should be reconsidered in pts with CKD stage >2 w/ 4 fold higher odds of HCQ levels - adjust dose for pts with renal impairment @RheumNow #RNL2023 https://t.co/JvaRJKJRPv

#RNL2023 Year in Review BE COMPLETE: P3 trial Bimekizumab for PsA in TNF inadequate responses at 16 weeks 160 mg BKZ SQ q4w vs PBO ACR50 43%, PBO 7% PASI 1000: BKZ 58.5% vs PBO 4.5% Safety: oral candidiasis: 2.6% BKZ vs PBO 0% @RheumNow https://t.co/bW00Wg6Cnf

Talk to me about candidiasis. BKZ showed increased safety signals for candida infections. I fear infxns may be under reported (after approval and in use) if patients see other physicians for treatment vs their rheumatologist/derm. Thoughts on this signal? #RNL2023 @rheumnow https://t.co/UPA5oP9G49

Could MTX every other week dosing be an option in patients with stable disease..? #RNL2023 https://t.co/EZRdQnuXjy

Urinary biomarkers in lupus nephritis ⁦@RheumNow⁩ and Kavanaugh discusses new urinary biomarkers in lupus nephritis that correlates with histology! #RNL2023 https://t.co/l1gQgFhviI

Year in Review by Dr. Cush and Dr. Kavanaugh Combo biologic therapy? Phase II study from GI colleagues for UC Guselkumab + golimumab - no additional safety concerns - improved clinical response - extrapolate to rheumatology use? #RNL2023 @RheumNow https://t.co/DirAovm1AX

✅ RheumNow Live 2023 #RNL2023 @RheumNow Which adverse events ⬇️ can be expected by patients & their rheumatologists when using #hydroxychloroquine for #Lupus? https://t.co/9zP8aJ4cGq

TYK2 in plaque psoriasis By Eric Ruderman #RNL2023 ⁦@RheumNow⁩ Safer? No lab monitoring And it works https://t.co/9Woen2q4hZ

Beautiful summary of GPA management by Dr.Carol Langford #RNL2023 ⁦@RheumNow⁩ https://t.co/FCwKN9tovX